Women with type 2 diabetes mellitus (T2DM) carry a disproportionate burden of visceral adipositydriven insulin resistance, partly attributable to sex-specific differences in fat distribution, adipokine biology, and hormonal modulation of insulin signaling. Despite constituting over half of the global diabetic population, women remain underrepresented in diabetes intervention trials, and sex-disaggregated outcome data from multimodal lifestyle interventions are scarce. Abdominal girth — the clinical surrogate of visceral adiposity — is a more sensitive marker of insulin resistance than BMI in women, and its reduction is a direct indicator of metabolic
normalization. This study examines the efficacy of the Comprehensive Diabetic Care (CDC) program in a predominantly female, high-BMI T2DM cohort, with abdominal girth reduction as the primary insulin resistance endpoint.